Galderma Group AG (XSWX:GALD) ROC (Joel Greenblatt) %: 130.09% (As of Dec. 2025) — 11% Above Median


XSWX:GALD Galderma Group AG XSWX:GALD
15 GF Score
Price CHF179.55
! 4 Warning Signs
View Full Analysis

What is Galderma Group AG ROC (Joel Greenblatt) %?

Galderma Group AG XSWX:GALD -0.42% 15 ROC (Joel Greenblatt) % is 130.09% as of Dec. 2025, which is 11% above its 10-year median of 116.92. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 977 Drug Manufacturers companies, Galderma Group AG ranks better than 94.78% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Galderma Group AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 130.09%.

The historical rank and industry rank for Galderma Group AG's ROC (Joel Greenblatt) % or its related term are showing as below:

XSWX:GALD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 108.49   Med: 116.92   Max: 121.97
Current: 118.49

During the past 5 years, Galderma Group AG's highest ROC (Joel Greenblatt) % was 121.97%. The lowest was 108.49%. And the median was 116.92%.

XSWX:GALD's ROC (Joel Greenblatt) % is ranked better than
94.78% of 977 companies
in the Drug Manufacturers industry
Industry Median: 11.37 vs XSWX:GALD: 118.49

Galderma Group AG's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Galderma Group AG  (XSWX:GALD) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Galderma Group AG ROC (Joel Greenblatt) % Related Terms


Galderma Group AG ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Galderma Group AG's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG ROC (Joel Greenblatt) % Chart

Galderma Group AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
0.00 0.00 108.49 121.97 116.92

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROC (Joel Greenblatt) % Get a 7-Day Free Trial 110.94 117.80 125.03 106.61 130.09

XSWX:GALD vs ZTS, UTHR, VTRS: ROC (Joel Greenblatt) % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galderma Group AG ROC (Joel Greenblatt) % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Galderma Group AG's ROC (Joel Greenblatt) % falls into.


XSWX:GALD
15GF Score
Galderma Group AG XSWX:GALD
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galderma Group AG ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(696.912 + 408.226 + 15.451) - (669.264 + 0 + 707.484)
=-256.159

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(711.632 + 418.373 + 54.985) - (823.198 + 0 + 762.633)
=-400.841

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Galderma Group AG for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=741.118/( ( (546.47 + max(-256.159, 0)) + (592.894 + max(-400.841, 0)) )/ 2 )
=741.118/( ( 546.47 + 592.894 )/ 2 )
=741.118/569.682
=130.09 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 130.09% mean?
Galderma Group AG (XSWX:GALD) has a ROC (Joel Greenblatt) % of 130.09% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Galderma Group AG and its competitors. This is 11% above median its historical median of 116.92. Over the past decade, Galderma Group AG's ROC (Joel Greenblatt) % has ranged from 108.49 to 121.97. According to the industry distribution chart, Galderma Group AG ranks #51 out of 977 companies in the Drug Manufacturers industry, placing it in the top 5.2%.
Is Galderma Group AG's ROC (Joel Greenblatt) % too high?
Galderma Group AG's current ROC (Joel Greenblatt) % of 130.09% is 11% above median its 10-year median of 116.92. Over the past 10 years, this metric has ranged from a low of 108.49 to a high of 121.97. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.37. Galderma Group AG's value of 130.09% is 1044.2% above this industry median. Based on the distribution chart, Galderma Group AG ranks #51 out of 977 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #51 out of 977 companies for ROC (Joel Greenblatt) %. This places Galderma Group AG in the top 5% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.37. Galderma Group AG's value of 130.09% is 1044.2% above this benchmark. Historically, Galderma Group AG's own ROC (Joel Greenblatt) % has ranged from 108.49 to 121.97 over the past decade. While the company's 10-year median is 116.92 vs. the industry median of 11.37, Galderma Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.37, based on 977 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galderma Group AG's current ROC (Joel Greenblatt) % of 130.09% is 1044.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Galderma Group AG and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current ROC (Joel Greenblatt) % is 130.09%, which is 11% above median its own 10-year median of 116.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current ROC (Joel Greenblatt) % of 130.09%. The current ROC (Joel Greenblatt) % is 130.09%, which is 11% above median its 10-year median of 116.92 and 1044.2% above the Drug Manufacturers industry median of 11.37. Galderma Group AG's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current ROC (Joel Greenblatt) % is 130.09% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galderma Group AG Business Description

Address Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score

Get the complete analysis for XSWX:GALD

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF179.55
Price